Chaperoning oncogenes: Hsp90 as a target of geldanamycin

Handbook of Experimental Pharmacology

Volumn 172, Issue , 2006, Pages 259-277

  Neckers, L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cancer; Geldanamycin; Genetic plasticity; Heat shock protein 90; Molecular chaperone; Molecularly targeted therapeutics; Oncogene

Indexed keywords

EID: 85099485992     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/3-540-29717-0_11     Document Type: Article

References (80)

1. Aghajanian C, Soignet S, Dizon DS, Pien CS, Adams J, Elliott PJ, Sabbatini P, Miller V, Hensley ML, Pezzulli S, Canales C, Daud A, Spriggs DR (2002) A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 8:2505-2511
2. Ali A, Bharadwaj S, OCarroll R, Ovsenek N (1998) HSP90 interacts with and regulates the activity of heat shock factor 1 in Xenopus oocytes. Mol Cell Biol 18:4949-4960
3. AnWG, Schulte TW, Neckers LM (2000) The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome. Cell Growth Differ 11:355-3360
4. Bagatell R, Paine-Murrieta GD, Taylor CW, Pulcini EJ, Akinaga S, Benjamin IJ, Whitesell L (2000) Induction of a heat shock factor 1-dependent stress response alters the cytotoxic activity of hsp90-binding agents. Clin Cancer Res 6:3312-3318
5. Bagatell R, Whitesell L (2004) Altered Hsp90 function in cancer: a unique therapeutic opportunity. Mol Cancer Ther 3:1021-1030
6. Basso AD, Solit DB, Chiosis G, Giri B, Tsichlis P, Rosen N (2002) Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function. J Biol Chem 277:39858-39866
7. Becker B, Multhoff G, Farkas B, Wild PJ, Landthaler M, Stolz W, Vogt T (2004) Induction of Hsp90 protein expression in malignant melanomas and melanoma metastases. Exp Dermatol 13:27-32
8. Bisht KS, BradburyCM, MattsonD,Kaushal A, Sowers A, Markovina S,Ortiz KL, Sieck LK, Isaacs JS, Brechbiel MW, Mitchell JB, Neckers LM, Gius D (2003) Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity. Cancer Res 63:8984-8995
9. Bonvini P, Gastaldi T, Falini B, Rosolen A (2002) Nucleophosmin- anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90- client tyrosine kinase: down-regulation of NPMALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17- demethoxygeldanamycin. Cancer Res 62:1559-1566
10. Bottaro DP, Liotta LA (2003) Out of air is not out of action. Nature 423:593-595
11. Chiosis G, Huezo H, Rosen N, Mimnaugh E, Whitesell L, Neckers L (2003) 17AAG: Low target binding affinity and potent cell activity: finding an explanation.Mol Cancer Ther 2:123-129
12. Chiosis G, Vilenchik M, Kim J, SolitD (2004) Hsp90: the vulnerable chaperone. Drug Discov Today 9:881-888
13. Dias S, Shmelkov SV, Lam G, Rafii S (2002) VEGF(165) promotes survival of leukemic cells by Hsp90-mediated induction of Bcl-2 expression and apoptosis inhibition. Blood 99:2532-2540
14. Druker BJ,Tamura S,Buchdunger E,OhnoS, SegalGM,Fanning S,ZimmermannJ,LydonNB (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2:561-566
15. Eiseman JL, Lan J, Lagattuta TF,HamburgerDR, Joseph E, Covey JM, EgorinMJ (2005) Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2-dimethylamino)ethyl] amino]geldanamycin (17DMAG, NSC 707545) in C.B-17 SCID mice bearing MDA-MB- 231 human breast cancer xenografts. Cancer Chemother Pharmacol 55:21-32
16. Eustace BK, JayDG (2004) Extracellular roles for the molecular chaperone, hsp90. Cell Cycle 3:1098-1100
17. Eustace BK, Sakurai T, Stewart JK, Yimlamai D, Unger C, Zehetmeier C, Lain B, Torella C, Henning SW, Beste G, Scroggins BT, Neckers L, Ilag LL, Jay DG (2004) Functional proteomic screens reveal an essential extracellular role for hsp90 alpha in cancer cell invasiveness. Nat Cell Biol 6:507-514
18. French BA, van Leeuwen F, Riley NE, Yuan QX, Bardag-Gorce F, Gaal K, Lue YH,Marceau N, French SW (2001) Aggresome formation in liver cells in response to different toxic mechanisms: role of the ubiquitin-proteasome pathway and the frameshift mutant of ubiquitin. Exp Mol Pathol 71:241-246
19. Fuino L, Bali P,Wittmann S, Donapaty S, Guo F, Yamaguchi H,Wang HG, Atadja P, Bhalla K (2003) Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B. Mol Cancer Ther 2:971-984
20. Fujimoto J, Shiota M, Iwahara T, Seki N, Satoh H, Mori S, Yamamoto T (1996) Characterization of the transforming activity of p80, a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t(2;5). Proc Natl Acad Sci U S A 93:4181-4186
21. FumoG,Akin C,MetcalfeDD,Neckers L (2004) 17-Allylamino-17- demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells. Blood 103:1078-1084
22. Gabai VL, Budagova KR, Sherman MY (2005) Increased expression of the major heat shock protein Hsp72 in human prostate carcinoma cells is dispensable for their viability but confers resistance to a variety of anticancer agents. Oncogene 24:3328-3338
23. Georget V, Terouanne B, Nicolas J-C, Sultan C (2002) Mechanism of antiandrogen action: key role of Hsp90 in conformational change and transcriptional activity of the androgen receptor. Biochemistry 41:11824-11831
24. GoetzMP, ToftDO, AmesMM,Erlichman C (2003) The Hsp90 chaperone complex as a novel target for cancer therapy. Ann Oncol 14:1169-1176
25. Gorre ME, Ellwood-Yen K, Chiosis G, Rosen N, Sawyers CL (2002) BCR-ABL point mutants isolated from patients with STI571-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. Blood 100:3041-3044
26. Gradin K, McGuire J, Wenger RH, Kvietikova I, Whitelaw ML, Toftgard R, Tora L, Gassmann M, Poellinger L (1996) Functional interference between hypoxia and dioxin signal transduction pathways: competition for recruitment of the Arnt transcription factor. Mol Cell Biol 16:5221-5531
27. Guo Y, Guettouche T, Fenna M, Boellmann F, PrattWB, Toft DO, Smith DF, Voellmy R (2001) Evidence for a mechanism of repression of heat shock factor 1 transcriptional activity by a multichaperone complex. J Biol Chem 276:45791-45799
28. HahnWC,Weinberg RA (2002)Modelling the molecular circuitry of cancer. Nat Rev Cancer 2:331-341
29. Hanahan D,Weinberg RA (2000) The hallmarks of cancer. Cell 100:57-70
30. Harris AL (2002)Hypoxia- a key regulatory factor in tumor growth.Nat Rev Cancer 2:38-47
31. Hur E, Kim HH, Choi SM, Kim JH, Yim S, Kwon HJ, Choi Y, Kim DK, Lee MO, Park H (2002) Reduction of hypoxia-induced transcription through the repression of hypoxiainducible factor-1alpha/aryl hydrocarbon receptor nuclear translocatorDNA binding by the 90-kDa heat-shock protein inhibitor radicicol. Mol Pharmacol 62:975-982
32. Isaacs JS, Jung YJ, Mimnaugh EG, Martinez A, Cuttitta F, Neckers LM (2002) Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway. J Biol Chem 277:29936-29944
33. Isaacs JS, Xu W, Neckers L (2003) Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell 3:213-217
34. Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC, Burrows FJ (2003) A highaffinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 425:407-410
35. Kim HR, Kang HS, Kim HD (1999) Geldanamycin induces heat shock protein expression through activation of HSF1 in K562 erythroleukemic cells. IUBMB Life 48:429-433
36. Kitano H (2003) Cancer robustness: tumour tactics. Nature 426:125
37. LAllemain G (2002) [Update on the proteasome inhibitor PS341]. Bull Cancer 89:29-30
38. La Rosee P, ODwyer ME, Druker BJ (2002) Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: a translational perspective. Leukemia 16:1213-1219
39. LuA,RanR,Parmentier-Batteur S,Nee A, SharpFR(2002) Geldanamycin induces heat shock proteins in brain and protects against focal cerebral ischemia. J Neurochem 81:355-364
40. Mabjeesh NJ, Post DE, Willard MT, Kaur B, Van Meir EG, Simons JW, Zhong H (2002) Geldanamycin induces degradation of hypoxia-inducible factor 1α protein via the proteasome pathway in prostate cancer cells. Cancer Res 62:2478-2482
41. Machida H,Matsumoto Y, Shirai M, Kubota N (2003) Geldanamycin, an inhibitor of Hsp90, sensitizes human tumour cells to radiation. Int J Radiat Biol 79:973-980
42. MarcuMG, Chadli A, Bouhouche I, Catelli M,NeckersLM(2000a) The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone. J Biol Chem 275:37181-37186
43. Marcu MG, Neckers LM (2003) The C-terminal half of heat shock protein 90 represents a second site for pharmacologic intervention in chaperone function. Curr Cancer Drug Targets 3:343-347
44. MarcuMG, Schulte TW,Neckers L (2000b)Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins. J Natl Cancer Inst 92:242-248
45. Matthews RC, Rigg G, Hodgetts S, Carter T, Chapman C, Gregory C, Illidge C, Burnie J (2003)Preclinical assessment of the efficacy ofmycograb, ahumanrecombinant antibody against fungal HSP90. Antimicrob Agents Chemother 47:2208-2216
46. Maulik G, Kijima T, Ma PC, Ghosh SK, Lin J, Shapiro GI, Schaefer E, Tibaldi E, Johnson BE, Salgia R (2002)Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer. Clin Cancer Res 8:620-627
47. Maxwell PH, Wiesener MS, Chang G-W, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, Ratcliffe PJ (1999) The tumor suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399:271-275
48. Mimnaugh EG, Chavany C, Neckers L (1996) Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin. J Biol Chem 271:22796-22801
49. MimnaughEG,Worland PJ,Whitesell L,NeckersLM(1995)Possible role for serine/threonine phosphorylation in the regulation of the heteroprotein complex between the hsp90 stress protein and the pp60v-src tyrosine kinase. J Biol Chem 270:28654-28659
50. Mimnaugh EG, Xu W, Vos M, Yuan X, Isaacs JS, Bisht KS, Gius D, Neckers L (2004) Simultaneous inhibition of hsp 90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum-derived cytosolic vacuolization, and enhances antitumor activity. Mol Cancer Ther 3:551-566
51. Minami Y, Kiyoi H, Yamamoto Y, Yamamoto K, Ueda R, Saito H, Naoe T (2002) Selective apoptosis of tandemly duplicated FLT3-transformed leukemia cells by Hsp90 inhibitors. Leukemia 16:1535-1540
52. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Fanourakis G, Gu X, Bailey C, Joseph M, Libermann TA, Treon SP,Munshi NC, Richardson PG,Hideshima T, Anderson KC (2002) Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A 99:14374-14379
53. Naoe T, Kiyoe H, Yamamoto Y, Minami Y, Yamamoto K, Ueda R, Saito H (2001) FLT3 tyrosine kinase as a target molecule for selective antileukemia therapy. Cancer Chemother Pharmacol 48:S27-S30
54. Neckers L (2002) Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med 8:S55-S61
55. NimmanapalliR,OBryan E,Huang M, Bali P, Burnette PK, Loughran T,Tepperberg J, JoveR, BhallaK(2002)Molecular characterization and sensitivity of STI-571 (imatinibmesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17- demethoxygeldanamycin. Cancer Res 62:5761-5769
56. Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio PM (2003) Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 3:347-361
57. Prodromou C, PearlLH(2003) Structure and functional relationships of Hsp90.Curr Cancer Drug Targets 3:301-323
58. Queitsch C, Sangster TA, Lindquist S (2002) Hsp90 as a capacitor of phenotypic variation. Nature 417:618-624
59. Rutherford SL, Lindquist S (1998) Hsp90 as a capacitor formorphological evolution. Nature 396:336-342
60. Sangster TA, Queitsch C (2005) The HSP90 chaperone complex, an emerging force in plant development and phenotypic plasticity. Curr Opin Plant Biol 8:86-92
61. Sawyers CL,Hochhaus A, Feldman E,GoldmanJM,MillerCB, OttmannOG, Schiffer CA,TalpazM, Guilhot F, DeiningerMW, Fischer T,OBrien SG, Stone RM,Gambacorti-Passerini CB, Russell NH, Reiffers JJ, Shea TC, Chapuis B, Coutre S, Tura S, Morra E, Larson RA, Saven A, Peschel C, Gratwohl A, Mandelli F, Ben-Am M, Gathmann I, Capdeville R, Paquette RL, Druker BJ (2002) Imatinib induces hematologic and cytogenetic responses in patients with chronicmyelogenous leukemia inmyeloid blast crisis: results of a phase II study. Blood 99:3530-3539
62. Schneider C, Sepp-Lorenzino L, Nimmesgern E, Ouerfelli O, Danishefsky S, Rosen N, Hartl FU (1996) Pharmacologic shifting of a balance between protein refolding and degradation mediated by Hsp90. Proc Natl Acad Sci U S A 93:14536-14541
63. Seizinger BR, Rouleau GA, Ozelius LJ, Lane AH, Farmer GE, Lamiell JM, Haines J, Yuen JW, CollinsD,Majoor-KrakauerDet al. (1988)VonHippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma. Nature 332:268-269
64. Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J, Sawyers CL (2002)Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2:117-125
65. Shiotsu Y, Neckers LM, Wortman I, An WG, Schulte TW, Soga S, Murakata C, Tamaoki T, Akinaga S (2000) Novel oxime derivatives of radicicol induce erythroid differentiation associated with preferential G(1) phase accumulation against chronicmyelogenous leukemia cells through destabilization of Bcr-Abl with Hsp90 complex. Blood 96:2284-2291
66. Siligardi G, Hu B, Panaretou B, Piper PW, Pearl LH, Prodromou C (2004) Co-chaperone regulation of conformational switching in the Hsp90 ATPase cycle. J Biol Chem 279:51989-51998
67. Solit D, Zheng F, Drobnjak M, Munster P, Higgins B, Verbel D, Heller G, Tong W, Cordon- Cardo C, Agus D, Scher H, Rosen N (2002) 17-allylamino-17- demthoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res 986-993
68. Soti C, Racz A, Csermely P (2002) A Nucleotide-dependent molecular switch controls ATP binding at the C-terminal domain of Hsp90. N-terminal nucleotide binding unmasks a C-terminal binding pocket. J Biol Chem 277:7066-7075
69. Stoler DL, Chen N, Basik M, Kahlenberg MS, Rodriguez-Bigas MA, Petrelli NJ, Anderson GR (1999) The onset and extent of genomic instability in sporadic colorectal tumor progression. Proc Natl Acad Sci U S A 96:15121-15126
70. Tacchini L, Dansi P, Matteucci E, Desiderio MA (2001) Hepatocyte growth factor signalling stimulates hypoxia inducible factor-1 (HIF-1) activity in HepG2 hepatoma cells. Carcinogenesis 22:1363-1371
71. Vanaja DK, Mitchell SH, Toft DO, Young CYF (2002) Effect of geldanamycin on androgen receptor function and stability. Cell Stress Chaperones 7:55-64
72. Waelter S, Boeddrich A, Lurz R, Scherzinger E, Lueder G, Lehrach H, Wanker EE (2001) Accumulation of mutant huntingtin fragments in aggresome-like inclusion bodies as a result of insufficient protein degradation. Mol Biol Cell 12:1393-1407
73. Wegele H, Muller L, Buchner J (2004) Hsp70 and Hsp90-a relay team for protein folding. Rev Physiol Biochem Pharmacol 151:1-44
74. Workman P (2004) Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone. Cancer Lett 206:149-157
75. Xiao N, Callaway CW, Lipinski CA, Hicks SD, DeFranco DB (1999) Geldanamycin provides posttreatment protection against glutamate-induced oxidative toxicity in a mouse hippocampal cell line. J Neurochem 72:95-101
76. Xu Y, Singer MA, Lindquist S (1999)Maturation of the tyrosine kinase c-src as a kinase and as a substrate depends on the molecular chaperone Hsp90. Proc Natl Acad Sci U S A 96:109-114
77. Yu X,Guo ZS,MarcuMG,Neckers L,NguyenDM, Chen GA, SchrumpDS (2002)Modulation of p53,ErbB1,ErbB2,andRaf-1 expressionin lungcancer cellsbydepsipeptide FR901228. J Natl Cancer Inst 94:504-513
78. ZagzagD,Nomura M, FriedlanderDR, Blanco C, Gagner JP,Nomura N,Newcomb EW(2003) Geldanamycin inhibits migration of glioma cells in vitro: a potential role for hypoxiainducible factor (HIF-1alpha) in glioma cell invasion. J Cell Physiol 196:394-402
79. Zhang H, Burrows F (2004) Targeting multiple signal transduction pathways through inhibition of Hsp90. J Mol Med 82:488-499
80. Zhao YG, Gilmore R, Leone G, CoffeyMC,Weber B, Lee PW (2001) Hsp90 phosphorylation is linked to its chaperoning function. Assembly of the reovirus cell attachment protein. J Biol Chem 276:32822-32827